glp-1 and dementia Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine Is it time to repurpose

The peptide's safety profile has been established through extensive animal studies and human clinical trials, with minimal side effects reported even during long-term administration protocols extending multiple years

This is less of an issue with sealed vials but is still a consideration

Compatibility

4 Clinical studies have observed that reducing adipose tissue through weight loss can improve migraine

By combining GLP-1 therapy with lifestyle changes, patients can maximize results while developing long-term, sustainable habits to optimize health and wellness

Were excited to find ways to continue bringing branded treatments to the platform across specialties